Skip to main content
. 2024 Oct 28;32(4):101361. doi: 10.1016/j.omtm.2024.101361

Figure 1.

Figure 1

Clinical course of each participant

Swimmer plot depicting the clinical course of each participant. Participant DVX201-002 received lymphodepleting chemotherapy 5 days after DVX201 infusion. Participant DVX201-009 had persistent SARS-CoV-2 detection in the lower respiratory tract but not in nasopharyngeal swabs (data not shown on the plot).